论文部分内容阅读
对我院32名空腹血糖>11.1mmol/L的初诊T2DM患者,采用诺和锐30特充联合二甲双胍治疗6个月,观察治疗前后的空腹血糖(FPG)、餐后2小时血糖(h2PG)、糖化血红蛋白(HbAIC)、空腹C肽(FCP)、餐后2小时C肽(h2CP)、体重指数(BM I)。结果:患者血糖较治疗前明显下降(P<0.01),C肽较治疗前明显升高(P<0.01)。结论:诺和锐30特充联合二甲双胍治疗初诊空腹血糖较高的T2DM患者疗效满意。
Thirty-two newly diagnosed T2DM patients with fasting blood glucose> 11.1mmol / L in our hospital were treated with Novo-Rui30 plus metformin for 6 months. The levels of fasting blood glucose (FPG), postprandial blood glucose (h2PG) HbAIC, fasting C-peptide (FCP), postprandial 2-hour C-peptide (h2CP) and body mass index (BMI). Results: The blood glucose of patients was significantly lower than that before treatment (P <0.01), C peptide was significantly higher than that before treatment (P <0.01). Conclusions: Novo-Rui30 combined with metformin treatment of newly diagnosed T2DM patients with high fasting plasma glucose was satisfactory.